Clinical Trial Results:
A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 18 weeks in Type 2 diabetic patients with insufficient glycaemic control (HbA1c 7.0-10%) despite background therapy with a sulfonylurea drug
Summary
|
|
EudraCT number |
2008-003118-86 |
Trial protocol |
HU |
Global completion date |
14 Jan 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
21 Apr 2019
|
First version publication date |
05 Apr 2015
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.